Chapter 2 Summary and Highlights
- Market Outlook
- Market Summary
Chapter 3 Market Overview
- Evolution of RNA Therapeutics
- History of RNA Therapeutics
- Development of RNA Therapeutics and Types
- DNA Therapeutics vs. RNA Therapeutics
- Clinical Need for RNA Therapeutics
- Increasing Disease Population and Economic Burden
- Limitations of Traditional Therapeutics
- Therapeutic Limitations of Biologics
- Poor Management of Chronic Diseases
- Limited Treatment for Rare Diseases
- RNA Therapeutics
- Antisense Oligonucleotide (ASO) as Therapeutics
- Small Interfering RNA (siRNA) as Therapeutics
- miRNA as Therapeutics
- Aptamers as Therapeutics
- mRNA as Therapeutics
- Manufacturing RNA-Based Biopharmaceuticals
- Chromatographic Purification Steps
- Delivery of RNA Therapeutics
- Polymer Conjugation/Chemical Modification
- Encapsulation
- Lipid-Based Nanoparticles
- Polymer Nanomaterials
- Silica Nanoparticles
- Carbon and Gold Nanomaterials
- GalNAc
- Institution and Hospital-Based RNA Therapeutics
- Regulatory Influence on the Market for RNA Therapeutics
- Impact of COVID-19
Chapter 4 Market Dynamics
- Market Dynamics
- Drivers
- Restraints
- Opportunities
Chapter 5 Target Disease and Disorders
- Overview of Common Diseases and Disorders for mRNA Therapeutics
- Cancer
- Infectious Diseases
- Cardiovascular Disease
- Lifestyle Disorders
- Respiratory Disorders
- Musculoskeletal Disorders
- Gastrointestinal Disorders
- Urology Disorders
- Nephrology Disorders
- Immune Disorders
- Neurological Disorders
- Rare Diseases
- Other Disorders
- Tobacco Smoking and Associated Diseases
- Infectious Diseases: COVID-19 Pandemic and mRNA Therapeutics
- Chronic Diseases: Expanding Horizon for mRNA Therapeutics
- Unmet Needs of Rare Diseases: mRNA Therapeutics
- Aging, Gender and Onset of Diseases
- Global Demographics
- U.S. Demographics
- European Demographics
- Japanese Demographics
Chapter 6 Pipeline and Clinical Trial Analysis
- mRNA Vaccines
- mRNA Therapeutics
- Clinical Trial Analysis
Chapter 7 Market Breakdown by Product
- Mechanism of Action of mRNA COVID Vaccines
- Three Most-Advanced mRNA Vaccines
Chapter 8 Market Breakdown by Region
- North America
- Canada
- Europe
- Asia-Pacific
- Japan
- South Korea
- China
- India
- Australia
- RoW
Chapter 9 Emerging Technologies and Developments
- Overview
- Nanoparticles
- Modified mRNA
- Automated mRNA Synthesis Kits
- Bio Platforms
Chapter 10 Patent Analysis
- Patent Analysis
- mRNA Publication
Chapter 13 Company Profiles
- ARCTUR U.S. THERAPEUTICS INC.
- BIONTECH SE
- CUREVAC N.V.
- GENNOVA BIOPHARMACEUTICALS LTD.
- MERCK KGAA
- MODERNA INC.
- NUTCRACKER THERAPEUTICS
- OMEGA THERAPEUTICS INC.
- STRAND THERAPEUTICS
- VAXESS TECHNOLOGIES INC.
List of Tables
Summary Table: Global Market for mRNA Therapeutics, by Type, Through 2028
Table 1: COVID-19: Total Cases and Deaths, by Select Country, 2023
Table 2: Pandemics of the 21st Century
Table 3: Global Prevalence of Breast Cancer Cases, by Country/Region, Through 2025
Table 4: Global Epidemiology of Colorectal Cancer Cases, by Region, Through 2030
Table 5: Global Cancer-Related Deaths, by Cancer Type, Through 2030
Table 6: Distribution of Global Cancer-Related Deaths, by Cancer Type, 2022
Table 7: Case Fatality Rate, Global Viral Outbreaks, 2020
Table 8: Global Incidence Share of Hypertension, by Patient Group Type, 2020
Table 9: Global Prevalence of Angina Pectoris and Stroke (Survivors), Through 2030
Table 10: Global Prevalence of CHF and Stroke, Through 2030
Table 11: Structural Heart Disease Management Through Medications
Table 12: BMI Categories Based on Increasing Health Risks
Table 13: Trends in Obesity Composition of the Global Population, Through 2025
Table 14: Obesity and Severe Obesity vs. General Population in the U.S., Through 2025
Table 15: Global Distribution of Diabetes, by Type
Table 16: Global Prevalence of Diabetes, by Type, Through 2040
Table 17: Global Prevalence of Key Symptomatic Musculoskeletal Disorders, Through 2025
Table 18: Global Deaths, by Type of Musculoskeletal Disorder, Through 2030
Table 19: Global Deaths from Digestive Diseases, by Region, Through 2025
Table 20: Global Distribution of Mortality, by Chronic Disease Type, 2019
Table 21: Global Distribution of DALYs, by Chronic Disease Type, 2019
Table 22: Estimated World Population and Annual Growth, by Age Group, Through 2030
Table 23: Total Global Population, by Select Country/Region, Through 2030
Table 24: U.S. Population Projections and Estimates, by Age Group, Through 2030
Table 25: Estimates of Anticipated U.S. Life Expectancy at Birth, by Gender, Through 2020
Table 26: European Population Estimates and Projections, by Age Group, Through 2030
Table 27: Japanese Population Estimates and Projections, by Age Group, Through 2030
Table 28: Clinical Trials on mRNA Vaccine Candidates, 2023
Table 29: Clinical Trials on mRNA Vaccine Candidates for Cancer Treatments, as of 2023
Table 30: Clinical Trials on mRNA Therapeutic Application
Table 31: Properties of BNT162b2 Vaccine
Table 32: Properties of mRNA-1273 Vaccine
Table 33: Properties of CVnCoV Vaccine
Table 34: Global Market for COVID Vaccines, by Region, Through 2028
Table 35: Global Market for Non-COVID mRNA Therapeutics, by Region, Through 2028
Table 36: Global Market for mRNA Therapeutics, by Region, Through 2028
Table 37: North American Market for mRNA Therapeutics, by Type, Through 2028
Table 38: European Market for mRNA Therapeutics, by Type, Through 2028
Table 39: Asia-Pacific Market for mRNA Therapeutics, by Type, Through 2028
Table 40: RoW Market for mRNA Therapeutics, by Type, Through 2028
Table 41: mRNA Patents: Top 10 Organizations
Table 42: Notable Patents for mRNA Therapeutics
Table 43: Some of the Notable Patents Related to mRNA Vaccines for Infectious Diseases
Table 44: Some of the Notable Patents Related to mRNA Vaccines for Cancer
Table 45: Notable Patents Focused on mRNA Delivery and Modification
Table 46: Recent M&A Deals on mRNA Therapeutics Company, 2006-2021
Table 47: Major Development of Company Profiles, 2021-2023
Table 48: BioNTech: Annual Revenue, 2021 and 2022
Table 49: BioNTech: News, 2021-2023
Table 50: BioNTech: ESG Developments, 2021
Table 51: BioNTech: Pipeline Products
Table 52: CureVac: Annual Revenue, 2021 and 2022
Table 53: CureVac: News, 2021-2023
Table 54: CureVac: Pipeline
Table 55: Merck: Annual Revenue, 2021 and 2022
Table 56: Merck: miRNA Product Portfolio
Table 57: Merck: Key Developments, Jan 2021-May 2023
Table 58: Moderna Inc.: Annual Revenue, 2021 and 2022
Table 59: Moderna Inc.: News, 2021-2023
Table 60: Moderna Inc.: Pipeline Products
Table 61: Nutcracker Therapeutics: Pipeline Products
Table 62: Strand Therapeutics: Pipeline Products
Table 63: Strand Therapeutics: News, 2021-2023
List of Figures
Summary Figure: Global Market for mRNA Therapeutics, by Type, 2021-2028
Figure 1: Development Timeline: COVID-19 mRNA Vaccines
Figure 2: Reasons for Increasing Pandemics
Figure 3: Benefits of Vaccination
Figure 4: Investment in RNA Therapeutics 2011 to 2021
Figure 5: Global Prevalence of Breast Cancer Cases, by Region/Country, 2015-2025
Figure 6: Global Cancer-Related Deaths, by Cancer Type, 2000-2030
Figure 7: Distribution of Global Cancer-Related Deaths, by Cancer Type, 2022
Figure 8: Case Fatality Rate Share, Global Viral Outbreaks, 2020
Figure 9: Global Incidence Share of Hypertension, by Patient Group Type, 2020
Figure 10: Global Prevalence of Angina Pectoris and Stroke (Survivors), 2004-2030
Figure 11: Global Prevalence of CHF and Stroke, 2004-2030
Figure 12: Trends in Obesity Composition of the Global Population, 2012-2025
Figure 13: Obesity and Severe Obesity vs. General Population in the U.S., 2018 and 2025
Figure 14: Global Distribution of Diabetes, by Type
Figure 15: Global Prevalence of Diabetes, by Type, 2018 and 2040
Figure 16: Global Prevalence of Key Symptomatic Musculoskeletal Disorders, 2012-2025
Figure 17: Global Deaths, by Type of Musculoskeletal Disorder, 2000-2030
Figure 18: Global Distribution of Mortality, by Chronic Disease Type, 2019
Figure 19: Global Distribution of DALYs, by Chronic Disease Type, 2019
Figure 20: Estimated World Population and Annual Growth, by Age Group, 2000-2030
Figure 21: Total Global Population, by Select Country/Region, 2000-2030
Figure 22: U.S. Population Estimates and Projections, by Age Group, 2000-2030
Figure 23: Estimates of Anticipated U.S. Life Expectancy at Birth, by Gender, 2005-2020
Figure 24: European Population Estimates and Projections, by Age Group, 2000-2030
Figure 25: Japanese Population Estimates and Projections, by Age Group, 2000-2030
Figure 26: Distribution of Clinical Trials on mRNA Vaccines, by Disease Indication, 2023
Figure 27: Distribution of mRNA Vaccine Candidates in Clinical Trials, by Phase, 2023
Figure 28: Distribution of mRNA Vaccine Candidates in Clinical Trials, by Mode of Administration, 2023
Figure 29: Clinical Trials on mRNA Therapeutics, Based on Recruiting Status, January 2020 to October 2023
Figure 30: Share of Clinical Trials on mRNA Therapeutics, With or Without Results, January 2020 to October 2023
Figure 31: Clinical Trials on mRNA Therapeutics, Based on Age Group, January 2020 to October 2023
Figure 32: Share of Clinical Trials on mRNA Therapeutics, Based on Gender, January 2020 to October 2023
Figure 33: Share of Clinical Trials on mRNA Therapeutics, by Trial Phase, January 2020 to October 2023
Figure 34: Share of Clinical Trials on mRNA Therapeutics, by Type of Funder, January 2020 to October 2023
Figure 35: Share of Clinical Trials on mRNA Therapeutics, by Enrollment Number, January 2020 to October 2023
Figure 36: Share of Clinical Trials on mRNA Therapeutics, by Interventional Mode, January 2020 to October 2023
Figure 37: Share of Clinical Trials on mRNA Therapeutics, by Type, January 2020 to October 2023
Figure 38: Global Market for mRNA Therapeutics, 2021-2028
Figure 39: Innovations in mRNA Therapeutics
Figure 40: mRNA Based Patent Publications, 2019-2021
Figure 41: Patents on mRNA Therapeutics, 2010-2021
Figure 42: Share of Patents on mRNA Therapeutics, by Patent Classification, 2010 to 2021
Figure 43: Funding in the mRNA Market, by Various Sources, 2021-2023
Figure 44: Top Three Companies: mRNA Vaccines and Therapeutics
Figure 45: Share of Key Growth Strategies of Major Companies, 2021-2023
Figure 46: BioNTech: Annual Revenue, 2021 and 2022
Figure 47: CureVac: Annual Revenue, 2020 and 2021
Figure 48: Merck: Annual Revenue, 2021 and 2022
Figure 49: Merck: Market Share, by Business Segment, 2022
Figure 50: Merck: Revenue Share, by Region, 2022
Figure 51: Moderna Inc.: Annual Revenue, 2021 and 2022
Figure 52: Moderna Inc.: Revenue Share, by Segment, 2022
